Identifying Post CAR-T Issues in Community Oncology Patients
Mazyar Shadman, MD, MPH, explains how community oncologists can care for their patient after they have been treated with chimeric antigen receptor T cells.
MB-106 Treatment Appears Safe and Effective in R/R B-Cell Malignancies
Mazyar Shadman, MD, MPH, discusses the results of his research on MB-106 as treatment for patients with relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Phase 1/2 Study Examines MB-106 in Various Positive B-cell Malignancies
Mazyar Shadman, MD, MPH, discusses the phase 1/2 clinical trial of MB-106 for patients with CD20 positive B-cell malignancies.
Investigating CD20 CAR T-Cell Therapy in R/R CLL and Other B-NHL Histologies
Mazyar Shadman, MD, MPH, discusses the use of MB-106 for the treatment of patients with relapsed or refractory B-cell nonHodgkin lymphoma and chronic lymphocytic leukemia.